【导读】环状RNA（circRNAs）已被证明在肿瘤发生和发展以及肿瘤免疫学中发挥着重要作用。然而，对circRNAs的全基因组特征及其在胆囊癌（GBC）的免疫学和免疫治疗中的作用的研究尚不充分。10月20日，上海中医药大学与复旦大学以及上海交通大学 ...

Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...

（原标题：近33亿美元！默沙东“牵手”礼新医药，PD-(L)1/VEGF领域交易频发） 21世纪经济报道记者 韩利明 上海报道 连日来，PD-（L）1/VEGF双特异性抗体领域迎来多起重磅交易。

最新研究速递 2024年10月17日，清华大学药学院唐海东课题组在《Cell Reports》杂志上发表了题为“PD-L1 protects tumor-associated dendritic cells from ferroptosis during immunogenic chemotherapy”的研究论文 最新研究速递 2024年10月17日，清华大学药学院唐海东课题组在《Cell ...

Key data: These results compare favourably to the 22.0-month median OS, 9.0-month median PFS, and 24-month OS rate of 45.5% from a registrational trial of anti-PD-1 and doublet chemotherapy in ...

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that anti-PD-L1 immunotherapy in combination with mutation-directed targeted therapy extended overall survival ...

"Palleon Pharmaceuticals reports Phase I/II trial results of E-602 for solid tumours" was originally created and published by ...

The test improved prediction of patient benefit from anti-PD-1 immune checkpoint inhibitors (ICIs) as a monotherapy and with ...

In July 2024, Checkpoint announced that the FDA accepted for review the resubmission of its BLA for cosibelimab as a complete response to the complete response letter (“CRL”) issued in December 2023 ...

an anti-PD-1 monoclonal antibody, versus zimberelimab or chemotherapy, in patients with front-line locally advanced or metastatic squamous or non-squamous NSCLC with a PD-L1 tumor proportion score of ...